• 1
    Bell NJ, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996; 10: 897904.
  • 2
    Blum RA, Shi H, Karol M, et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 101323.
  • 3
    Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995; 20(Suppl. 1): S79.
  • 4
    Bruley des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion, and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8(3): 30914.
  • 5
    Dammann HG, Fuchs W, Richter G, et al. Influence of lansoprazole 15 mg and omeprazole 20 mg and 40 mg on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 35964.
  • 6
    Tolman KG. Comparison of the effects of lansoprazole and omeprazole on 24-hour gastric pH in normal male volunteers. J Clin Gastroenterol 1997; 24: 6570.
  • 7
    Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 3918.
  • 8
    Regardh GG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1991; 21(Suppl. 118): 99104.
  • 9
    Chun AHC, Eason CJ, Shi HH, et al. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther 1995; 17: 4417.
  • 10
    Chun AHC, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 83342.
  • 11
    Sharma VK, Ugheoke EA, Vasudeva R, et al. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. Aliment Pharmacol Ther 1998; 12: 11714.
  • 12
    Zimmermann A, Walters JK, Katona B, et al. Alternative methods of proton pump inhibitor administration. Consult Pharm 1997; 12: 9908.
  • 13
    Sharma VK, Vasudeva R, Howden CW. A study of the effects of per-gastrostomy administration of an alkaline suspension of omeprazole on intragastric acidity. Aliment Pharmacol Ther 1999; 13: 10916.
  • 14
    Sharma VK, Heinzelmann EJ, Steinberg EN, et al. Nonencapsulated intact granule omeprazole is effective in gastric acid suppression. Am J Gastroenterol 1997; 92: 84851.
  • 15
    Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56(23 Suppl. 4): S1821.
  • 16
    Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension — a liquid formulation of lansoprazole — effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94(7): 18137.
  • 17
    Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan W-J. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health Syst Pharm 2001; 58: 15129.
  • 18
    Taubel JJ, Sharma VK, Chiu YL, Lukasik NL, Pilmer BL, Pan WJ. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-hour intragastric pH. Aliment Pharmacol Ther 2001; 15: 180717.
  • 19
    Freston JW, Chiu YL, Pan WJ, et al. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol 2001; 6: 205865.
    Direct Link:
  • 20
    Roberts KW, Pitcher WD, Cryer B. Effect of lansoprazole suspension versus continuous intravenous ranitidine on gastric pH of mechanically ventilated intensive care unit patients. Crit Care Med 2000; 28(Suppl. 12): A185(567/T155).
  • 21
    Metropolitan Life Insurance Company. Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64(1): 29.
  • 22
    Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 65780.
  • 23
    Huang JQ, Goldwater DR, Thomson ABRT, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 19.
  • 24
    Claessens AAMC, Heerdink ER, Van Eijk JThM, Lamers CBHW, Leufkens HGM. Safety review in 10,008 users of lansoprazole in daily practice. Pharmacoepidemiol Drug Safety 2000; 9: 38391.
  • 25
    Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole. The US Clinical Trial Experience. Drug Safety 1999; 20: 195205.